Get the Stockscreener App
1.55
4.73%
0.07
After Hours:
1.55
Actinium Pharmaceuticals Inc stock is traded at $1.55, with a volume of 222.21K.
It is up +4.73% in the last 24 hours and up +19.23% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.48
Open:
$1.5
24h Volume:
222.21K
Relative Volume:
0.37
Market Cap:
$46.79M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-0.847
EPS:
-1.83
Net Cash Flow:
$-47.49M
1W Performance:
+3.33%
1M Performance:
+19.23%
6M Performance:
-13.89%
1Y Performance:
-82.25%
1-Day Range:
$1.47
$1.59
1-Week Range:
$1.35
$1.59
52-Week Range:
$1.06
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.55 | 46.79M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.52 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesATNM - PR Newswire
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action ... - Bluefield Daily Telegraph
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - GlobeNewswire Inc.
Actinium Pharma (ATNM) Receives Buy Rating with $4.00 Price Targ - GuruFocus
Actinium Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your RightsATNM - PR Newswire
Investors who lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about pending Class ActionATNM - ACCESS Newswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending - GlobeNewswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - GlobeNewswire Inc.
2025-05-10 | Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline | NYSEAM:ATNM | Press Release - Stockhouse
2025-05-09 | Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your RightsATNM | NYSEAM:ATNM | Press Release - Stockhouse
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ATNM Stock News: Actinium Pharmaceuticals, Inc. Investors Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the ATNM Class Action - ACCESS Newswire
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit - Business Wire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium - GlobeNewswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a ... - Eagle-Tribune
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for InvestorsContact The Gross Law Firm - Morningstar
Contact Levi & Korsinsky by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM) - ACCESS Newswire
The Gross Law Firm Notifies Shareholders of Actinium Pharmaceuticals, Inc. (ATNM) of a Class ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies Shareholders of Actinium - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - PR Newswire
Actinium enrolls first patient on the trial studying Iomab-ACT - TipRanks
Actinium Announces Enrollment of First Patient in the Iomab-ACT - GuruFocus
Actinium Pharmaceuticals (ATNM) Begins Pioneering Iomab-ACT Trial with CAR-T Therapy | ATNM Stock News - GuruFocus
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center - Yahoo Finance
Lost Money on Actinium Pharmaceuticals, Inc.(ATNM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
Renaissance Technologies LLC Purchases 63,400 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Kirby McInerney LLP Urges Investors in Actinium - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ... - Bluefield Daily Telegraph
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) Shareholders - PR Newswire
JPMorgan Chase & Co. Acquires 110,141 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - GuruFocus
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors ... - Eagle-Tribune
Class Action Filed Against Actinium Pharmaceuticals, Inc. - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To Discuss Their Options - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to - Bluefield Daily Telegraph
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation - Kilgore News Herald
Actinium Pharmaceuticals Inc’s results are impressive - uspostnews.com
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc.(ATNM) - PR Newswire
The Attractiveness of Investing In Actinium Pharmaceuticals Inc (ATNM) is Growing - knoxdaily.com
Actinium Pharmaceuticals Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Market Watch Highlights: Actinium Pharmaceuticals Inc (ATNM) Ends on an Downturn Note at 1.30 - DWinneX
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Actinium Presents Data Showing ATNM-400 is More Efficacious than - GuruFocus
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium - GlobeNewswire
Actinium Pharma (ATNM) Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models - StreetInsider
ATNM Showcases Promising Preclinical AML Results with Actimab-A - GuruFocus
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
2.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):